Janux Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $-8,512 | $439 |
Gross Profit | -541 | -519 | -9,550 | 439 |
EBITDA | -45,118 | -34,897 | -28,510 | -35,332 |
EBIT | -35,416 | -29,022 | -35,842 | |
Net Income | -33,858 | -23,508 | -20,216 | -28,059 |
Net Change In Cash | 0 | 0 | -8,512 | 439 |
Free Cash Flow | -24,286 | -17,395 | -16,767 | -2,256 |
Cash | 52,446 | 73,743 | 430,605 | 26,754 |
Basic Shares | 61,902 | 61,791 | 56,832 | 54,628 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $10,588 | $8,083 | $8,612 | $3,637 |
Gross Profit | 8,528 | 6,128 | 8,612 | 3,637 |
EBITDA | -98,847 | -71,024 | -66,250 | -32,816 |
EBIT | -100,907 | -72,979 | -67,091 | -32,929 |
Net Income | -68,994 | -58,293 | -54,154 | -32,559 |
Net Change In Cash | 10,588 | 8,083 | 8,612 | 3,637 |
Cost of Revenue | 15,844 | 28,585 | ||
Free Cash Flow | -44,173 | -52,425 | -49,367 | -18,458 |
Cash | 430,605 | 19,205 | 51,426 | 35,582 |
Basic Shares | 53,751 | 44,016 | 41,469 | 41,243 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.55 |
2025-03-31 | -$0.38 |
2024-12-31 | -$0.36 |
